Syndax Pharmaceuticals (SNDX) Liabilities and Shareholders Equity (2015 - 2026)

Syndax Pharmaceuticals' Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $472.7 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 26.23% year-over-year to $472.7 million; the TTM figure through Mar 2026 stood at $2.2 billion (down 5.2% YoY), while the FY2025 annual figure was $529.7 million, down 26.92% from the prior year.
• Liabilities and Shareholders Equity was $472.7 million for Q1 2026 at Syndax Pharmaceuticals, down from $529.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $724.8 million in Q4 2024 to a low of $359.7 million in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $503.0 million across 5 years, with a median of $476.9 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity jumped 54.5% in 2022, then decreased 26.92% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $497.2 million in 2022, then rose by 23.26% to $612.9 million in 2023, then gained by 18.26% to $724.8 million in 2024, then fell by 26.92% to $529.7 million in 2025, then decreased by 10.77% to $472.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $472.7 million (Q1 2026), $529.7 million (Q4 2025), and $551.8 million (Q3 2025), per Business Quant data.